Retratutide 20mg research peptide vial – triple GLP-1 GIP glucagon receptor agonist for fat loss and metabolic health optimization

Fat Loss, Lean Recomposition, Total Body Transformation

Retatrutide 20mg | Triple Incretin Agonist for Fat Loss & Metabolic Health | Vietnam Peptides

Name: Retatrutide 20mg | Triple Incretin Agonist for Fat Loss &amp; Metabolic Health | Vietnam Peptides
SKU: 763
Availability: InStock

2.999.999 ₫

Retratutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist — the most mechanistically advanced metabolic peptide currently in active Phase III clinical development. Delivering up to 24% body weight reduction in Phase II trials, its tri-agonist architecture simultaneously suppresses appetite, enhances insulin dynamics, and elevates resting energy expenditure through three distinct hormonal pathways. Supplied as a 20mg research vial with Bacteriostatic Water included.

Categories: Fat Loss, Lean Recomposition, Total Body Transformation Tags: 20mg peptide vial, advanced fat loss peptide, appetite suppression peptide, BAC water included, biohacking peptide, biohacking Southeast Asia, body composition peptide, body recomposition peptide, clinical weight loss peptide, energy expenditure peptide, expat wellness Vietnam, fat loss peptide, fat oxidation peptide, GIP receptor agonist, GLP-1 GIP glucagon peptide, GLP-1 receptor agonist, glucagon receptor agonist, HJ Pharma peptide, incretin receptor peptide, insulin sensitivity peptide, lean mass preservation peptide, lean recomposition peptide, longevity peptide, LY3437943, lyophilized peptide, metabolic health peptide, metabolic optimization peptide, metabolic peptide Vietnam, obesity research peptide, peptide for fat loss, peptide for weight management, peptide protocol, peptide Southeast Asia, peptide vial 20mg, peptide Vietnam, performance peptide, premium metabolic peptide, research grade peptide, research peptide Vietnam, Retatrutide, Retratutide, Retratutide 20mg, semaglutide alternative peptide, tirzepatide alternative, total body transformation peptide, tri-agonist peptide, triple incretin agonist, visceral fat peptide, weight loss peptide Vietnam, wellness peptide Vietnam

Description
Reviews (0)

Overview

Retratutide (LY3437943) is a triple incretin receptor agonist — simultaneously targeting GLP-1, GIP, and glucagon receptors — representing one of the most mechanistically advanced metabolic peptides currently in active clinical research. Where earlier-generation GLP-1 agonists work through a single pathway, Retratutide’s tri-agonist architecture engages three distinct hormonal axes that regulate appetite, energy balance, fat oxidation, and metabolic rate in concert.

Emerging Phase II clinical data has demonstrated exceptional body composition outcomes, with subjects achieving up to 24% total body weight reduction in 48-week trials — results that substantially exceed those observed with dual-agonist compounds. Retratutide’s glucagon receptor component contributes meaningfully to resting energy expenditure, making it one of the few research peptides capable of driving fat loss through both appetite suppression and active metabolic acceleration simultaneously.

Each vial contains 20mg of lyophilized Retratutide peptide, manufactured to research-grade purity standards, and includes pharmaceutical-grade bacteriostatic water (BAC water) for reconstitution. Designed for advanced biohackers, metabolic health researchers, and individuals pursuing serious body recomposition, this compound represents the frontier of precision metabolic science.

Key Benefits

Triple Receptor Engagement: Simultaneous activation of GLP-1, GIP, and glucagon receptors provides a multi-axis approach to metabolic regulation unavailable from single or dual-agonist compounds.
Superior Fat Loss Outcomes: Phase II trials demonstrated up to 24.2% mean body weight reduction — placing Retratutide among the highest-efficacy metabolic peptides in active clinical research.
Enhanced Resting Energy Expenditure: Glucagon receptor agonism meaningfully increases basal metabolic rate, supporting fat oxidation beyond what appetite suppression alone can achieve.
Appetite and Satiety Regulation: GLP-1 and GIP receptor activation works synergistically to modulate hunger signaling, gastric emptying, and caloric intake without requiring willpower-dependent dietary restriction.
Body Composition Optimization: Clinical data suggests preferential fat mass reduction with relative lean mass preservation — a critical distinction for body recomposition goals.
Metabolic Health Markers: Research indicates meaningful improvements in fasting glucose, insulin sensitivity, and lipid profiles alongside body weight reduction.
Favorable Tolerability Profile: Clinical trial data demonstrates tolerability comparable to established GLP-1 compounds, with dose-dependent gastrointestinal effects as the primary noted side effect class.

Popular Use Cases

Individuals pursuing advanced fat loss protocols seeking superior results beyond first-generation GLP-1 compounds
Biohackers and longevity-focused researchers optimizing metabolic health and body composition
Those exploring tri-agonist peptide research at the frontier of metabolic science
Athletes and high-performance individuals in structured cut or recomposition phases
Wellness professionals studying incretin receptor pathway modulation
Individuals with metabolic health goals seeking a research-grade compound with clinical-stage data support
Expats and international wellness travelers seeking premium peptides not yet widely accessible in mainstream markets

Who Commonly Uses Retratutide

Retratutide attracts a specific profile of sophisticated wellness optimizers: those who have already explored first and second-generation metabolic peptides and are seeking materially superior outcomes. This includes experienced biohackers familiar with GLP-1 compounds who want the enhanced efficacy of tri-agonist architecture, metabolic health researchers tracking cutting-edge clinical trial data, and high-performance individuals who understand that body composition is a function of multiple hormonal axes — not just appetite suppression alone.

It also resonates with longevity-focused individuals who understand the deep connection between metabolic health, adiposity, and biological aging — recognizing that precision fat loss is not merely aesthetic but a fundamental pillar of healthspan extension.

Product Details

Peptide: Retratutide (LY3437943) — Triple GLP-1/GIP/Glucagon Receptor Agonist
Dosage per Vial: 20mg lyophilized powder
Format: Single vial — research-grade lyophilized peptide
BAC Water Included: Yes — pharmaceutical-grade bacteriostatic water for reconstitution
Storage (Lyophilized): 2–8°C refrigerated, protected from light
Storage (Reconstituted): 2–8°C, use within 28 days
Purity: ≥99% (research grade)
Mechanism: Triple incretin receptor agonist (GLP-1R, GIPR, GcgR)

Storage & Handling

Lyophilized Retratutide peptide should be stored at 2–8°C (refrigerator temperature) in a sterile, light-protected environment prior to reconstitution. Avoid exposure to direct sunlight, excessive heat, or repeated freeze-thaw cycles, which can degrade peptide integrity. For long-term storage of unreconstituted vials beyond 6 months, storage at −20°C is recommended.

Reconstitute using the included pharmaceutical-grade bacteriostatic water, adding the BAC water slowly along the vial wall to minimize foaming. Once reconstituted, store at 2–8°C and use within 28 days. Do not shake; swirl gently to mix. Always use sterile technique when withdrawing doses.

Research & Scientific Interest

Retratutide (LY3437943) was developed by Eli Lilly and entered Phase II clinical trials where it demonstrated unprecedented efficacy in body weight reduction. A landmark 48-week Phase II study published in The New England Journal of Medicine (Jastreboff et al., 2023) reported mean weight reduction of 17.5% at 12mg and up to 24.2% at the highest dose tested — outcomes that substantially exceeded those of semaglutide and tirzepatide at comparable timepoints.

The scientific interest in Retratutide stems from its mechanistic depth. By simultaneously agonizing three incretin receptors, the compound creates compound metabolic effects: GLP-1 receptor activation reduces appetite and slows gastric emptying; GIP receptor activation enhances insulin secretion and may contribute to fat tissue signaling; glucagon receptor agonism increases hepatic glucose output and resting energy expenditure. The net result is a multi-directional metabolic shift that single-pathway approaches cannot replicate.

Ongoing Phase III trials will provide long-term safety and efficacy data, but the existing Phase II dataset already places Retratutide at the forefront of metabolic peptide research.

Frequently Asked Questions

What is Retratutide and how does it differ from semaglutide or tirzepatide?

Retratutide (LY3437943) is a triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist. Retratutide’s additional glucagon receptor agonism increases resting energy expenditure and adds a fat oxidation dimension that single and dual agonists cannot provide — contributing to its superior clinical weight loss outcomes in Phase II trials.

What clinical evidence exists for Retratutide’s efficacy?

A Phase II clinical trial published in The New England Journal of Medicine (Jastreboff et al., 2023) reported mean body weight reductions of 17.5% at 12mg and up to 24.2% at the highest dose over 48 weeks. These outcomes substantially exceed Phase II results from both semaglutide and tirzepatide at comparable timepoints, positioning Retratutide as potentially the most efficacious metabolic peptide yet studied in clinical trials.

How does the tri-agonist mechanism work?

Retratutide activates three receptor pathways simultaneously. GLP-1 receptor agonism reduces appetite, slows gastric emptying, and promotes satiety. GIP receptor agonism enhances insulin secretion and interacts with adipose tissue signaling. Glucagon receptor agonism increases hepatic glucose output and, critically, raises resting energy expenditure — meaning the body burns more calories at rest. Together, these three pathways create compounding metabolic effects unavailable from single or dual-agonist approaches.

Does Retratutide preserve lean muscle mass during fat loss?

Clinical trial data suggests Retratutide preferentially reduces fat mass relative to lean mass, a critical distinction for body recomposition goals. While all significant caloric deficit protocols carry some risk of lean mass reduction, the tri-agonist mechanism’s metabolic acceleration component appears to support a favorable fat-to-lean mass loss ratio compared to caloric restriction alone. Combining Retratutide research with resistance training protocols is a common approach among advanced wellness optimizers.

What does the 20mg vial contain?

Each vial contains 20mg of lyophilized (freeze-dried) Retratutide peptide, manufactured to ≥99% purity. Pharmaceutical-grade bacteriostatic water (BAC water) is included for reconstitution. The lyophilized format maximizes stability and shelf life prior to reconstitution. Once reconstituted, store at 2–8°C and use within 28 days.

How should Retratutide be stored?

Store lyophilized Retratutide at 2–8°C in a sterile, light-protected environment. Avoid heat, direct sunlight, and repeated freeze-thaw cycles. For storage beyond 6 months, −20°C freezer storage is recommended for unreconstituted vials. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Always use sterile technique when drawing doses.

Can Retratutide be stacked with other peptides?

Retratutide’s mechanism operates through incretin receptor pathways, which are distinct from those of many recovery and longevity peptides. It is frequently discussed alongside BPC-157 (for gastrointestinal mucosal support during adaptation phases), peptide recovery compounds, and broader longevity stacks. As with any multi-compound protocol, experienced researchers typically introduce Retratutide as a standalone before adding additional compounds, allowing baseline response assessment first.

What are the most commonly reported side effects in clinical trials?

In Phase II clinical trials, the most commonly reported side effects were gastrointestinal in nature: nausea, vomiting, decreased appetite, and diarrhea — consistent with the class effects of GLP-1 receptor agonists. These were predominantly mild to moderate and occurred most frequently during dose escalation phases. Standard protocol in clinical research involved gradual dose escalation to improve tolerability. The overall safety profile was described as comparable to established GLP-1-class compounds.

Is Retratutide the same as LY3437943?

Yes. LY3437943 is the development code assigned by Eli Lilly, while Retratutide is the INN (International Nonproprietary Name) for the same molecule. In research literature and clinical trial registrations, both designations refer to the identical tri-agonist GLP-1/GIP/glucagon receptor compound. The peptide research community uses both names interchangeably.

How does glucagon receptor agonism contribute to fat loss?

Glucagon receptor activation increases hepatic glucose output and, more relevantly for fat loss, elevates resting energy expenditure — the body burns more calories even at rest. This thermogenic-adjacent effect creates an energy deficit component that operates independently of dietary intake, distinguishing Retratutide’s mechanism from GLP-1-only or GLP-1/GIP compounds. It represents a meaningful addition to the tri-agonist formula’s overall metabolic impact.

What makes Retratutide a premium metabolic peptide?

Several factors distinguish Retratutide: its unprecedented Phase II efficacy data (up to 24.2% weight reduction), its mechanistic tri-agonist architecture unavailable from earlier compounds, its active Phase III clinical development by a major pharmaceutical company (Eli Lilly), and the depth of its impact across multiple metabolic parameters simultaneously. For serious metabolic health researchers and biohackers, it represents the current frontier of evidence-based metabolic optimization.

Does Retratutide impact metabolic health markers beyond weight?

Yes. Phase II clinical data demonstrated improvements in multiple cardiometabolic markers including fasting blood glucose, HbA1c, insulin resistance, triglycerides, and blood pressure alongside body weight reduction. These systemic metabolic improvements are consistent with the compound’s multi-receptor mechanism and suggest value beyond body weight endpoints alone for those focused on comprehensive metabolic health optimization.

Where is Retratutide in its clinical development?

As of the latest available data, Retratutide (LY3437943) completed Phase II trials with exceptional efficacy results and has advanced to Phase III clinical development by Eli Lilly. Phase III trials will provide larger-scale safety and long-term efficacy data across broader populations. The compound is not yet commercially approved, making research-grade access the primary means of studying its properties at this stage of development.

How does Retratutide relate to longevity and healthy aging?

The connection between adiposity, metabolic dysfunction, and biological aging is well-established in longevity research. Excess visceral fat drives chronic inflammation, insulin resistance, and accelerated cellular aging. Retratutide’s capacity to drive meaningful fat mass reduction — particularly visceral adiposity — positions it as a relevant tool in comprehensive longevity protocols. Its improvements in metabolic health markers (glucose, insulin sensitivity, lipids) further align with established biomarkers of biological aging and healthspan.

Where can I find the peer-reviewed research on Retratutide?

The primary reference is the Phase II trial by Jastreboff et al. (2023) published in The New England Journal of Medicine, which remains the landmark dataset for Retratutide’s efficacy. Additional mechanistic research on GLP-1/GIP/glucagon tri-agonist signaling is available across multiple pharmacology and metabolic research journals. A curated selection of key references is provided in the Research References section below.

Research References

Jastreboff, A.M., et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 389(6), 514–526. PubMed
Coskun, T., et al. (2022). “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism, 34(7), 976–988. PubMed
Nauck, M.A., & D’Alessio, D.A. (2022). “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.” Cardiovascular Diabetology, 21, 169. PubMed
Willard, F.S., et al. (2020). “Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.” JCI Insight, 5(17). PubMed
Holst, J.J. (2019). “The incretin system in healthy humans: The role of GIP and GLP-1.” Metabolism, 96, 46–55. PubMed
Day, J.W., et al. (2009). “A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.” Nature Chemical Biology, 5(10), 749–757. PubMed
Pi-Sunyer, X., et al. (2015). “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” New England Journal of Medicine, 373(1), 11–22. PubMed
Lincoff, A.M., et al. (2023). “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 389(24), 2221–2232. PubMed
Jensen, M.D., et al. (2014). “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” Journal of the American College of Cardiology, 63(25 Pt B), 2985–3023. PubMed
ClinicalTrials.gov (2023). “A Study of LY3437943 (Retatrutide) in Participants With Obesity.” Identifier: NCT04881760. ClinicalTrials.gov

Invest in Your Metabolic Future

Retratutide represents the convergence of three decades of incretin research into a single, precision-engineered peptide — one designed to accomplish simultaneously what previous generations of metabolic compounds could only partially address. For the serious wellness optimizer, longevity researcher, or advanced biohacker, Retratutide 20mg offers access to the frontier of clinical metabolic science: a tri-agonist architecture backed by landmark Phase II data, formulated at research-grade purity, and built for those who approach body composition with the same rigor they bring to every dimension of performance.

Engineered at the intersection of metabolic science and human optimization. For those who demand more than incremental progress.

Reviews

There are no reviews yet.

Be the first to review “Retatrutide 20mg | Triple Incretin Agonist for Fat Loss & Metabolic Health | Vietnam Peptides”